Stem Cell Breakthrough for ARK - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stem Cell Breakthrough for ARK

First-in-human Moorfields trial improves vision in patients with previously untreatable aniridia-related keratopathy

  • September 2, 2026

  • 2 min

Share

  • 1

    A new stem cell treatment has improved vision in patients with aniridia-related keratopathy (ARK), a previously untreatable genetic eye condition.

  • 2

    The treatment was developed by researchers at Moorfields Eye Hospital and the UCL Institute of Ophthalmology and tested in nine patients.

  • 3

    Patients showed substantial improvements in ocular surface scores, decreasing from an average of 9.4 to 5.9 after three months.

  • 4

    Vision improved by an average of 24 letters on the ETDRS eye test, equivalent to almost five lines on a standard vision chart.

  • 5

    Researchers plan to advance this treatment to a larger clinical trial with the goal of NHS acceptance.

Original Source(s)

Stem Cell Breakthrough for ARK

  • September 2, 2026

Related Content

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

Glaucoma Trials Tracker

Access Glaucoma Physician's listing of all active interventional clinical trials related to glaucoma.

  • September 1, 2026

  • 14 min
Hybrid How-To: <br>High-Definition Hybrids</br>